Vivus is a biopharmaceutical company focused on commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health for U.S., Europe and other world markets. The company offers Qsymia, which is in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. For more information, visit the company’s Web site: http://www.vivus.com
Let us hear your thoughts below: